Evidence map›Paper›PMID 34961488›Full record

ArticleBMC cancer2021

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.

Ross S Greenberg, Jake A Ruddy, Brian J Boyarsky, William A Werbel, Jacqueline M Garonzik-Wang, Dorry L Segev, Philip H Imus

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ross S GreenbergDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jake A RuddyDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brian J BoyarskyDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William A WerbelDepartment of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jacqueline M Garonzik-WangDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dorry L SegevDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. dorry@jhmi.edu.
Philip H ImusDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021.

resultsRates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted.

conclusionsTwo-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.

Indexed as

Immunization Schedule2019-nCoV Vaccine mRNA-1273AgedAntibodies, ViralBNT162 VaccineCohort StudiesCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedmRNA VaccinesMultiple MyelomaProspective StudiesVaccination Hesitancy2019-nCoV Vaccine mRNA-1273Antibodies, ViralBNT162 VaccineCOVID-19 VaccinesmRNA VaccinesVaccines, SyntheticAntibodyCOVID-19mRNA vaccinationMultiple myelomaSARS-CoV-2

Identifiers

PMID34961488
PMCPMC8711688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.